A Phase 4 interventional study of Bupivacaine HCl in Postoperative Pain, sponsored by Heron Therapeutics. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Heron Therapeutics · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.
Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 310th largest by enrollment, is one of 27 that started in 2018, is one of 133 in phase 4, and was the 154th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.
Browse Pain, Postoperative studies →57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Hitit University · Sites in Turkey
Ages 18–75
Wah Medical college , POF hospital · Sites in Pakistan
Ages 18–60
Tianjin First Central Hospital · Sites in China
Ages 18–80
Erkan Gol · Sites in Turkey
Ages 18+ · Women only
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
364 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 57 · Phase 3 53 · Phase 4 133
First in 2004; this study’s year is marked. 27 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 75 across 4,829 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 364 interventional studies. Of the 258 that completed or were terminated, 106 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 364 have an industry lead sponsor. The 10 most frequent:
Heron Therapeutics is the lead sponsor of 26 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 12 (86%) have results posted.
20 studies in Pain, Postoperative by Heron Therapeutics: none open now, 1 under way, none of them phase 3. Of 18 finished, 16 (89%) have results posted.
Among the 20 studies in Pain, Postoperative by Heron Therapeutics, this one is the 17th largest by enrollment, is one of 4 that started in 2018, is one of 5 in phase 4, and was the 9th registered.
Heron Therapeutics’s Pain, Postoperative studies by the year they started, since 2015.
22 of the studies testing bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07650760Wah Medical college , POF hospitalComparison of Intraperitoneal Bupivacaine and Saline Irrigation for Pain Relief After Laparoscopic Cholecystectomy | 2026-12 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT02381353Mayo ClinicExparel Injection for Postoperative Orbital Pain | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 364 studies testing bupivacaine in Pain, Postoperative, from their registry updates:
Among Heron Therapeutics’s 20 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
This is a Phase 4, randomized, open-label study of bupivacaine HCl administered either by instillation into the surgical site or by injection into the surgical site in subjects undergoing bilateral submuscular augmentation mammoplasty under general anesthesia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bupivacaine HCI 150 mg via instillation (75 mg into each pectoral pocket)
Drug: Bupivacaine HCl
Bupivacaine HCI 150 mg via injection (75 mg into each pectoral pocket)
Drug: Bupivacaine HCl
Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)
Cmax
Maximum observed bupivacaine plasma concentration
Time frame: Through 72 hours after start of study drug administration
AUClast
Area under the bupivacaine plasma concentration-time curve through 72 hours postdose
Time frame: Through 72 hours after start of study drug administration
AUCinf
Area under the bupivacaine plasma concentration-time curve from the start of study drug administration extrapolated to infinity
Time frame: Through 72 hours after start of study drug administration
Tmax
Time to maximum bupivacaine plasma concentration
Time frame: Through 72 hours after start of study drug administration
λz
Apparent terminal elimination rate constant
Time frame: Through 72 hours after start of study drug administration
t1/2el
Apparent terminal elimination half-life
Time frame: Through 72 hours after start of study drug administration
| Milestone | Bupivacaine HCI Via Instillation | Bupivacaine HCl Via Injection |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 14 |
| Not completed | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Maximum observed bupivacaine plasma concentration
| ng/mL | Bupivacaine HCI Via Instillation | Bupivacaine HCI Via Injection |
|---|---|---|
| Cmax | 1110 ± 347 | 1110 ± 469 |
Area under the bupivacaine plasma concentration-time curve through 72 hours postdose
| h∙ng/mL | Bupivacaine HCI Via Instillation | Bupivacaine HCl Via Injection |
|---|---|---|
| AUClast | 9620 ± 6190 | 8610 ± 2400 |
Area under the bupivacaine plasma concentration-time curve from the start of study drug administration extrapolated to infinity
| h∙ng/mL | Bupivacaine HCI Via Instillation | Bupivacaine HCl Via Injection |
|---|---|---|
| AUCinf | 9850 ± 6760 | 8710 ± 2340 |
Time to maximum bupivacaine plasma concentration
| hours | Bupivacaine HCI Via Instillation | Bupivacaine HCl Via Injection |
|---|---|---|
| Tmax | 1.03 (0.53 to 1.58) | 0.73 (0.18 to 1.25) |
Apparent terminal elimination rate constant
| /h | Bupivacaine HCI Via Instillation | Bupivacaine HCl Via Injection |
|---|---|---|
| λz | 0.0572 ± 0.0169 | 0.0963 ± 0.0227 |
Apparent terminal elimination half-life
| hours | Bupivacaine HCl Via Instillation | Bupivacaine HCl Via Injection |
|---|---|---|
| t1/2el | 13.5 ± 5.03 | 7.69 ± 2.33 |
Collected over From the time the subject signed the Informed Consent Form through Day 28.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bupivacaine HCl Via Instillation | 0/15 (0%) | 0/15 (0%) | 15/15 (100%) |
| Bupivacaine HCl Via Injection | 0/15 (0%) | 0/15 (0%) | 14/15 (93.3%) |
| Event | Bupivacaine HCl Via Instillation | Bupivacaine HCl Via Injection |
|---|---|---|
| NauseaGastrointestinal disorders | 10/15 | 10/15 |
| VomitingGastrointestinal disorders | 9/15 | 6/15 |
| HeadacheNervous system disorders | 3/15 | 3/15 |
| TachycardiaCardiac disorders | 3/15 | 1/15 |
| HypotensionVascular disorders | 3/15 | 3/15 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/15 | 0/15 |
| ConstipationGastrointestinal disorders | 2/15 | 1/15 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 1/15 | 2/15 |
| Pruritus generalisedSkin and subcutaneous tissue disorders | 2/15 | 1/15 |
| DizzinessNervous system disorders | 1/15 | 1/15 |
| Age, Categorical(Participants) | Bupivacaine HCI Via Instillation | Bupivacaine HCI Via Injection | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 15 | 15 | 30 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Bupivacaine HCI Via Instillation | Bupivacaine HCI Via Injection | Total |
|---|---|---|---|
| Mean | 28.2 ± 6.67 | 32.8 ± 6.53 | 30.5 ± 6.89 |
| Sex: Female, Male(Participants) | Bupivacaine HCI Via Instillation | Bupivacaine HCI Via Injection | Total |
|---|---|---|---|
| Female | 15 | 15 | 30 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Bupivacaine HCI Via Instillation | Bupivacaine HCI Via Injection | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 6 | 15 |
| Not Hispanic or Latino | 6 | 9 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Bupivacaine HCI Via Instillation | Bupivacaine HCI Via Injection | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 12 | 12 | 24 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Bupivacaine HCI Via Instillation | Bupivacaine HCI Via Injection | Total |
|---|---|---|---|
| United States | 15 | 15 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Sep 2018 to primary completion in Oct 2018, 0 months.
Results were first posted in Oct 2026, 8 years after primary completion.
Of 542 phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 0 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine